Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
4.840
+0.320 (7.08%)
At close: May 16, 2025, 4:00 PM
4.760
-0.080 (-1.65%)
After-hours: May 16, 2025, 6:51 PM EDT
Amylyx Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Amylyx Pharmaceuticals stock ranges from a low of $4.00 to a high of $16. The average analyst price target of $9.80 forecasts a 102.48% increase in the stock price over the next year.
Price Target: $9.80 (+102.48%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Amylyx Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 2 | 3 |
| Hold | 4 | 4 | 4 | 4 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | +65.29% | May 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $16 | Strong Buy | Maintains | $12 → $16 | +230.58% | May 9, 2025 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $4 → $10 | Hold → Buy | Upgrades | $4 → $10 | +106.61% | May 7, 2025 |
| Mizuho | Mizuho | Hold → Buy Upgrades $3 → $7 | Hold → Buy | Upgrades | $3 → $7 | +44.63% | Apr 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +147.93% | Mar 5, 2025 |
Financial Forecast
Revenue This Year
n/a
from 87.37M
Revenue Next Year
131.58K
EPS This Year
-1.92
from -4.43
EPS Next Year
-1.55
from -1.92
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 677,250 | 26.3M | ||
| Avg | n/a | 131,580 | 10.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 19,849.8% | ||
| Avg | - | - | 8,168.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.67 | -1.00 | -1.14 | ||
| Avg | -1.92 | -1.55 | -1.70 | ||
| Low | -2.21 | -2.12 | -2.22 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.